mertansine

Mertansine is a tubulin inhibitor and an antibody-conjugable maytansinoid alkaloid. The IC50 of Mertansine against HCT-15 and A431 cells is 0.750 and 0.04nM.

Cantuzumab mertansine (SB-408075; huC242-DM1), an antibody-drug conjugate (ADC), comprises the potent maytansine derivative (DM1) linked to the humanized monoclonal antibody (huC242) targeting CanAg. Demonstrating cytotoxicity against colon cancer cells, this compound shows extensive antitumor effectiveness across various CanAg-positive human tumor xenografts [1] [2].

Lorvotuzumab mertansine is an antibody-drug conjugate (ADC) that can be used in life science related research. The CAS number is 1008106-64-6.

Mertansine-¹³C,d₃ (DM1-¹³C,d₃) is a ¹³C and deuterium-labeled form of Mertansine. Mertansine (DM1) is a microtubule inhibitor and a conjugatable maytansinoid alkaloid intended to reduce systemic toxicity associated with maytansinoids and improve tumor-targeted delivery. It can be conjugated to monoclonal antibodies through linker molecules to form antibody-drug conjugates (ADCs).

DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate that combines the microtubulin inhibitor DM1 (mertansine), an antibody-conjugatable maytansinoid designed to reduce systemic toxicity and improve tumor-specific delivery, with the linker DBCO-PEG4-Ahx, for developing antibody drug conjugates (ADCs).

DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for developing antibody-drug conjugates (ADCs). This conjugation aims to mitigate systemic toxicity associated with maytansine while improving tumor-specific delivery, leveraging DM1's ability as an antibody-conjugatable maytansinoid.

SC-VC-PAB-DM1 is a drug-linker conjugate used in Antibody-Drug Conjugates (ADC), combining DM1 (Mertansine, a tubulin inhibitor) with the SC-VC-PAB[1] ADC linker to deliver potent antitumor activity.

Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds to CD56 (NCAM1) and can be used to synthesize the antibody-drug conjugate Lorvotuzumab mertansine.

Cantuzumab is a monoclonal antibody that targets the CanAg antigen and possesses antitumor activity; it is used to synthesize the ADC compound cantuzumab mertansine. By binding to CanAg, cantuzumab mediates the endocytosis of the ADC complex into cells, where it cleaves to release the cytotoxic payload, thereby achieving highly efficient and specific tumor killing.

SHR-A1201 is an antibody-drug conjugate (ADC) targeting HER2. This compound is composed of a humanized anti-HER2 antibody, the linker SMCC, and the cytotoxic payload Mertansine, which is a microtubule inhibitor. SHR-A1201 is utilized in research for HER2-positive breast cancer.

DM1 Impurity is a byproduct found in Mertansine (DM1).